- Home
- CULP vs ANL Comparison
CULP vs ANL Comparison
Compare CULP & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CULP | ANL |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Textiles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CULP | ANL |
|---|---|---|
| Price | $3.78 | $1.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 37.7K | 25.3K |
| Earning Date | 12-10-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,919,000.00 | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $0.88 |
| 52 Week High | $5.94 | $2.99 |
Technical Indicators
Market Signals| Indicator | CULP | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 50.17 |
| Support Level | $3.60 | $0.88 |
| Resistance Level | $4.04 | $1.59 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 23.68 | 67.67 |
Price Performance
Historical ComparisonAbout CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.